Moving beyond Titers.

Autor: Brooks BD; Department of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USA.; Inovan Inc., Fargo, ND 58103, USA., Beland A; College of Osteopathic Medicine, Rocky Vista University, Parker, CO 80112, USA., Aguero G; College of Osteopathic Medicine, Rocky Vista University, Parker, CO 80112, USA., Taylor N; College of Osteopathic Medicine, Rocky Vista University, Parker, CO 80112, USA., Towne FD; College of Osteopathic Medicine, Rocky Vista University, Parker, CO 80112, USA.
Jazyk: angličtina
Zdroj: Vaccines [Vaccines (Basel)] 2022 Apr 26; Vol. 10 (5). Date of Electronic Publication: 2022 Apr 26.
DOI: 10.3390/vaccines10050683
Abstrakt: Vaccination to prevent and even eliminate disease is amongst the greatest achievements of modern medicine. Opportunities remain in vaccine development to improve protection across the whole population. A next step in vaccine development is the detailed molecular characterization of individual humoral immune responses against a pathogen, especially the rapidly evolving pathogens. New technologies such as sequencing the immune repertoire in response to disease, immunogenomics/vaccinomics, particularly the individual HLA variants, and high-throughput epitope characterization offer new insights into disease protection. Here, we highlight the emerging technologies that could be used to identify variation within the human population, facilitate vaccine discovery, improve vaccine safety and efficacy, and identify mechanisms of generating immunological memory. In today's vaccine-hesitant climate, these techniques used individually or especially together have the potential to improve vaccine effectiveness and safety and thus vaccine uptake rates. We highlight the importance of using these techniques in combination to understand the humoral immune response as a whole after vaccination to move beyond neutralizing titers as the standard for immunogenicity and vaccine efficacy, especially in clinical trials.
Databáze: MEDLINE